# Telix Pharmaceuticals

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/telix-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/telix-pharmaceuticals

## Timeline

- **2026-Q3**: Part 2 Expansion — Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
- **2026-03-10**: Primary Objectives Met — Telix announces Part 1 achieved all primary safety and dosimetry goals.
- **2025-Q4**: Part 1 Completion — Enrollment for the safety and dosimetry portion of the study concludes.
- **2024-Q1**: Trial Initiation — ProstACT GLOBAL Phase 3 study begins enrollment.

## Recent coverage (1 stories)

### Telix Pharmaceuticals Hits Key Milestone in Phase 3 Prostate Cancer Trial
2026-03-10 00:58:12 · Sentiment: Positive · Impact: 7/10 · Sources: 4

Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Full story: https://getbiobrief.com/story/prostact-phase-3-primary-objectives-achieved

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.